PNU-96391A (OSU6162) antagonizes the development of behavioral sensitization induced by dopamine agonists in a rat model for Parkinson's Disease

Neuropharmacology

Volumn 43, Issue 5, 2002, Pages 817-824

  Nichols, N F ^a   Cimini, M G ^a   Haas, J V ^a   Staton, B A ^a   Tedroff, J ^b   Svensson, K A ^a  

^a PFIZER INC   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

6 OH DA lesions; Dyskinesias; L DOPA; Quinpirole; Rotational behavior

Indexed keywords

3 [3 (METHYLSULFONYL)PHENYL] 1 PROPYLPIPERIDINE; BENSERAZIDE; DECARBOXYLASE INHIBITOR; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG METABOLITE; LEVODOPA; PNU 180222; PNU 96391A; QUINPIROLE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; MALE; MEDIAL FOREBRAIN BUNDLE; NEUROCHEMISTRY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; ROTATION; TASK PERFORMANCE;

ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; HOMOVANILLIC ACID; LEVODOPA; MALE; MEDIAL FOREBRAIN BUNDLE; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; PIPERIDINES; QUINPIROLE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; STEREOTYPED BEHAVIOR; SYMPATHECTOMY, CHEMICAL; SYMPATHOLYTICS;

EID: 0036801619     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(02)00144-2     Document Type: Article

References (22)

1. Bordet R., Ridray S., Carboni S., Diaz J., Sokoloff P., Schwartz J.-C. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc. Natl. Acad. Sci. 94:1997;3363-3367.
2. Carey R.J. Chronic L-dopa treatment in the unilateral 6-OH-DA rat: evidence for behavioral sensitization and biochemical tolerance. Brain Res. 568:1991;205-214.
3. Carey R.J., Pinheiro-Carrera M., Tomaz C., Houston J.P. Early L-DOPA treatment initially retards but later enhances dopamine receptor supersensitivity following unilateral dopamine denervation. Brain. Res. 658:1994;145-154.
4. Cenci M.A., Lee C.S., Bjorklund A. L-Dopa-induced dyskinesias in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10:1998;2694-2706.
5. Ekesbo A., Andren P.E., Gunne L.M., Tedroff J. PNU-96391A inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease. Neuroreport. 8:1997;2567-2570.
6. Ekesbo A., Torstensson R., Hartvig P., Carlsson A., Sonesson C., Waters N., Tedroff J., Langstrom B. Effects of the substituted (S)-3-phenylpiperidine, (-)-OSU-6162, on PET measurements of [11C]SCH23390 and [11C]raclopride binding in primate brains. Neuropharmacol. 38:1999;331-338.
7. Ekesbo A., Andren P.E., Gunne L.M., Sonesson C., Tedroff J. Motor effects of PNU-96391A in primates with unilateral 6-hydroxydopamine lesions. Eur. J. Pharmacol. 389:2000;193-199.
8. 2 receptor-ligand on L-DOPA-induced dyskinesias in MPTP monkeys. Eur. J. Pharmacol. 412:2001;247-254.
9. Henry B., Crossman A.R., Brotchie J.M. Characterization of enhanced behavioral responses to L-Dopa following repeated administration in the 6-Hydroxy-dopamine-lesioned rat model of Parkinson's disease. Exp. Neurol. 151:1998;334-342.
10. Henry B., Crossman A.R., Brotchie J.M. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on pre-proenkephalin-A and pre-proenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Experimental Neurology. 155:1999;204-220.
11. Horstink M.W., Zijlmans J.C., Pasman J.W., Berger H.J., van't Hof M.A. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. J. Neurol. Neurosurg. Psychiatry. 53:1990;224-226.
12. ILAR, 1996. Guide for the care and use of laboratory animals. Institute of Laboratory Animal Resources, Comission on Life Sciences, National Research Council. National Academy Press, Washington D.C. ISBN 0-309-05377-3.
13. Jenner P. Pathophysiology and biochemistry of dyskinesia; clues for the development of non-dopaminergic treatments. J. Neurol. 247:(Suppl 2):2000;II.
14. Kapur S., Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry and Neuroscience. 25:2000;161-166.
15. Marin C., Jimenez A., Bonastre M., Vila M., Agid Y., Hirsch E.C., Tolosa E. LY293558, an AMPA glutamate receptor antagonist prevents and reverses levodopa-induced motor alterationsin Parkinsonian rats. Synpase. 42:2001;40-47.
16. Milliken G.A., Johnson D.E. Analysis of Messy Data Volume 1: Designed Experiments. 1992;Chapman & Hall/CRC, New York, NY.
17. Nutt J.G. Levodopa-induced dyskinesias: review, observations and speculations. Neurology. 40:1990;340-345.
18. Pirker W., Tedroff J., Ponten H., Andren P., Hurd Y.L. Coadministration of (-)-OSU6162 with L-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OH-DA lesions. Exp. Neurol. 169:2001;122-134.
19. Sonesson C., Lin C.-H., Hansson L.O., Waters N., Svensson K., Carlsson A., Smith W.W., Wilkstrom H. Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: Synthesis and structure-activity relationships. J. Med. Chem. 37:1994;2735-2753.
20. Tedroff J., Ekesbo A., Sonesson C., Waters N., Carlsson A. Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease. Neurology. 53:1999;1605-1606.
21. Tedroff J., Torstenson R., Hartvig P., Sonesson C., Waters N., Carlsson A., Neu H., Fasth K.J., Langstrom B. Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements in subhuman primates: evidence for tone-dependent normalization of striatal dopaminergic activity. Synapse. 28:1998;280-287.
22. Verhagen Metman L., Konitsiotis S., Chase T.N. Pathophysiology of motor response complications in Parkinson's Disease: Hypotheses on the Why, Where and What. Mov. Dis. 15:2000;3-8.